Clinical Trial Update: Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) [Phase 2]

View source ↗

Summary

Phase 2 trial of elosulfase alfa (BMN 110) in pediatric patients under 5 with Morquio A syndrome (MPS IVA) has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Iva

Drugs mentioned

• VIMIZIM (Elosulfase alfa)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-07-06